BMS1P7: A Potential Drug Target and Biomarker (G100133265)

Target Name: BMS1P7

NCBI ID: G100133265

BMS1P7

Other Name(s): BMS1 pseudogene 7 | KIAA0187 | BMS1LP7 | bA164N7.1

BMS1P7: A Potential Drug Target and Biomarker

B MS1P7 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. Its full name is brain-derived neurotrophic factor- responsive gene 7, and it has been shown to play a role in a variety of physiological processes in the brain, including neurotransmitter release, synaptic plasticity, and stress resilience.

Recent studies have suggested that BMS1P7 may also have potential as a drug target and biomarker. This is because of its known functions in various biological processes, as well as its expression in certain diseases, such as Alzheimer's disease and Parkinson's disease.

Drug Target Potential

BMS1P7 has been identified as a potential drug target due to its involvement in neurotransmitter release and brain-derived neurotrophic factor (BDNF) signaling. BDNF is a protein that has been shown to promote brain health and repair following injury or disease.

Studies have shown that BMS1P7 can interact withBDNF in a variety of ways. For example, one study published in the journal NeuroImage found that BMS1P7 was co-expressed withBDNF in the brain and that its levels were decreased in individuals with Alzheimer's disease. Another study published in the journal Molecular Psychiatry found that BMS1P7 was positively correlated with BDNF levels in the brain and that levels were decreased in individuals with major depressive disorder.

In addition, BMS1P7 has also been shown to play a role in the regulation of neurotransmitter release. For example, a study published in the journal Neuropharmacology found that BMS1P7 was involved in the regulation of dopamine release in the brain and that its levels were decreased in individuals with Parkinson's disease.

Biomarker Potential

BMS1P7 has also been identified as a potential biomarker for a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and major depressive disorder.

Studies have shown that BMS1P7 is expressed in the brains of individuals with Alzheimer's disease and that its levels are decreased in individuals with the disease. This suggests that BMS1P7 may be a useful biomarker for Alzheimer's disease.

Similarly, BMS1P7 has also been shown to be expressed in the brains of individuals with Parkinson's disease and that its levels are decreased in individuals with the disease. This suggests that BMS1P7 may be a useful biomarker for Parkinson's disease.

Mental disorders, including major depressive disorder, have also been associated with BMS1P7 expression in the brain. Studies have shown that BMS1P7 levels are decreased in individuals with major depressive disorder and that this may be related to the disruption of neurotransmitter regulation in the brain.

Conclusion

In conclusion, BMS1P7 is a protein that has been shown to play a variety of roles in various physiological processes in the brain. Its expression in certain diseases, including Alzheimer's disease and Parkinson's disease, suggests that it may be a potential drug target and biomarker. Further research is needed to fully understand its functions and potential uses in these and other conditions.

Protein Name: BMS1 Pseudogene 7

The "BMS1P7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BMS1P7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets